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Glioblastoma (GBM) are lethal primary brain tumours whose pathogenesis is aided, at least partly, via a protumorigenic microenvironment. This study investigated whether microglia, a cell component of the GBM
microenvironment, mediates pro-tumorigenic properties via the action of cyclophilin A (CypA), a potent secretable chemokine and cytoprotectant that signals via the cell surface receptor, CD147. To this end, intracellular and
secreted CypA expression was assessed in human primary microglia and BV2 microglial cells treated with the
endotoxin, lipopolysaccharide (LPS) and the oxidative stress inducer, LY83583. We report that human primary
microglia and BV2 microglia both express CypA and CD147, and that BV2 microglial cells secrete CypA in
response to pro-inﬂammatory and oxidative stimuli. We also demonstrate for the ﬁrst time that recombinant CypA
(rCypA; 1nM–1000nM) dose-dependently increased wound healing and reduced basal cell death in BV2 microglial cells. To determine the cell–signalling pathways involved, we probed microglial cell lysates for changes in
ERK1/2 and AKT phosphorylation, IκB degradation, and IL-6 secretion using Western blot and ELISA analysis. In
summary, BV2 microglial cells secrete CypA in response to inﬂammatory and oxidative stress, and that rCypA
increases cell viability and chemotaxis. Our ﬁndings suggest that rCypA is a pro-survival chemokine for microglia
that may inﬂuence the GBM tumour microenvironment.

1. Introduction
Glioblastoma (GBM; WHO: grade IV astrocytoma) is the most common, aggressive, and lethal form of astrocytoma. This tumour is typiﬁed
by progressive and diffuse cancer cell inﬁltrative properties within the
brain, and hence the inability of complete surgical resection of the
tumour. Although concomitant radiotherapy and chemotherapy can
prolong patient survival, the tumour will invariably recur, hence the need
to identify new therapeutic targets critical for GBM tumour progression.
To this end, GBM are multicellular in nature due to the inﬁltration of
microglia and macrophages, which comprise up to 30% of the tumour
mass (Graeber et al., 2002; Watters et al., 2005), and are thought to play a
role in tumour invasiveness (Wu and Watabe, 2017). Glioma cells secrete
a variety of growth factors, cytokines, and matrix proteases, which
facilitate the recruitment of microglia, as well as inﬂuence their role

within the tumour environment (Graeber et al., 2002; Hoelzinger et al.,
2007; Watters et al., 2005). One potentially pro-tumorigenic factor that is
over-expressed in GBM is cyclophilin A (CypA); a multifunctional protein
whose elevated intracellular levels are associated with adverse outcomes
in many cancers including GBM (Han et al., 2010; Handschumacher
et al., 1984; Ryffel et al., 1991; Willenbrink et al., 1995). Moreover, we
recently reported that Kaplan-Meier analysis of two large GBM datasets
demonstrated that high CypA expression leads to a relative reduction in
patient survival of approximately 3 months (Matthews et al., 2018).
CypA is an abundant cellular protein that was ﬁrst discovered as the
main target for the immunosuppressive drug, cyclosporine A (Handschumacher et al., 1984; Ryffel et al., 1991; Willenbrink et al., 1995).
Among its functions, CypA contributes to protein folding and assembly
and intracellular trafﬁcking, and the regulation of cytokine gene
expression (Handschumacher et al., 1984; Ivery, 2000; Kofron et al.,
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1991). In response to some pathological conditions, such as inﬂammation, hypoxia, and oxidative stress (Jin et al., 2000; Obchoei et al., 2015;
Seko et al., 2004; Sherry et al., 1992; Suzuki et al., 2006), CypA is
secreted into the extracellular environment. Extracellular CypA is a
potent chemokine that induces chemotaxis in monocytes, neutrophils,
eosinophils, and T cells (H. Kim et al., 2005; L. Wang et al., 2010).
Interestingly cyclosporine A reportedly inhibits GBM cell proliferation in
organotypic rat brain slices and mouse brains (Sliwa et al., 2007).
Furthermore, cyclosporine A has been shown to enhance the chemotherapeutic effects of cisplatin and to induce apoptosis in glioma cells
(Han et al., 2010; Zupanska et al., 2005).
Extracellular CypA can stimulate the ERK1/2, p38/MAPK, JNK, AKT/
PKB, and NFκB signalling pathways via CD147, the main receptor for
CypA (H. Kim et al., 2005; Kim et al., 2009). CD147 is frequently
over-expressed in cancerous tissues, with up to 86% of tumours testing
positive for CD147 (Riethdorf et al., 2006). Likewise, CD147 expression
is elevated in human glioblastomas, with higher CD147 expression being
associated with poorer patient outcomes (Riethdorf et al., 2006; Tian
et al., 2013; M. Yang et al., 2013). CypA-induced CD147 receptor signalling can result in biological effects such as increased Bcl-2 expression,
production of matrix metalloproteases (MMPs), cell migration, cell proliferation and cell differentiation (Jin et al., 2000; H. Kim et al., 2005;
Seko et al., 2004; Sherry et al., 1992). Moreover, exogenous CypA has
been shown to promote cell proliferation through ERK1/2 and p38 MAPK
signalling in lung cancer, pancreatic cancer cell lines (Howard et al.,
2005; Li et al., 2006; H. Yang et al., 2007) and via CD147 in cholangiocarcinoma cells (Obchoei et al., 2015).
The aims of this study were to examine if extracellular CypA plays a
role in promoting microglial cell viability and chemotaxis, and whether
microglia secrete CypA. We therefore examined the expression of CypA
and CD147 proteins in human and murine microglial cell lines, pro-cell
survival signalling events (ERK1/2 and AKT), and cellular effects
(migration/chemotaxis and proliferation/viability) of exogenous recombinant CypA (rCypA) in the BV2 murine microglial cell line. We also
investigated whether CypA is secreted by BV2 microglial cells and human
primary microglia in response to lipopolysaccharide (LPS) and oxidative
stress.

(0.05 mg/mL), streptomycin (0.1 mg/mL) and maintained in a CO2 (5%)
incubator at 37  C. For cell signalling studies, BV2 cells were seeded at
1.6  105 cells per well (24 well plate) and treated with LPS (1 μg/mL,
Sigma, USA), ROS generator 6-anilinoquinoline-5,8-quinone (LY83583,
Sigma), or rCypA protein. For CypA secretion studies, culture supernatants were centrifuged, transferred to fresh tubes and stored at -80  C
prior to use. Cells were lysed using cytosolic extraction buffer (10 mM
HEPES; 3 mM MgCl2; 14 mM KCl; 5% glycerol; 0.2% IPEGAL) containing
phosphatase and protease inhibitors (Roche, USA). Cell lysates were
cleared, protein concentration calculated using protein assay solution
(Bio-Rad, Australia), and the supernatants stored at -80  C prior to use.

2. Materials and methods

2.5. Cell proliferation assays

2.1. Generation of puriﬁed recombinant CypA protein (rCypA)

BV2 microglial cells were seeded at 5  103 cells/well (24 well plate
format) and incubated at 37  C (5% CO2) for 24 h. Following incubation,
cells were treated with vehicle (PBS) or rCypA (ﬁnal concentration 1 nM,
10 nM or 100 nM), and incubated at 37  C (5% CO2) for the required time
points (24, 48 and 72 h). Cells were trypsinised with 100 μL of TrypLE
express (Life Technologies) and combined with an equal mixture of trypan blue. Viable (trypan blue exclusion) and dead cells (trypan blue
positive) were counted using a haemocytometer.

2.3. Western blotting
Western blot analysis was completed as previously described (MacDougall et al., 2017). Brieﬂy, total cell proteins were separated by
SDS-PAGE, transferred to PVDF membranes and analysed using the Gel
Doc EZ imager (Bio-Rad). Membranes were blocked in TBS-Tween containing ovalbumin (0.1%), followed by incubation with primary antibodies (pERK, Total-ERK, and CD147 Santa Cruz, USA; pAKT, total AKT
and IκB Cell Signalling Technology, USA; β-tubulin, Abcam, United
Kingdom; CypA, Biomol, Germany; all antibodies at 1:5000 dilution)
overnight at 4  C with gentle rocking. Membranes were washed and
probed with anti-mouse or anti-rabbit IgG horseradish peroxidase conjugated secondary antibodies (GE Lifesciences, USA). Immunoreactive
bands were visualized using ECL Plus (Amersham) chemiluminescent
detection reagent and quantiﬁed by densitometry. Total loaded protein
levels in gel lanes were also determined by visualising the loaded proteins on TGX stain free gels (Bio-Rad) using the Gel Doc EZ imager
(Bio-Rad).
2.4. IL-6 cytokine expression
BV2 cells were incubated overnight in DMEM without serum, then
treated with rCypA (100 nM) for a period of 24 h. Cytokine secretion of
IL-6 was determined by ELISA (BD OptEIATM; BD Biosciences, USA) and
compared to cells treated with vehicle.

A pET28a plasmid expression vector encoding the rat CypA sequence
6xHis-tag was transformed into E. coli KRX cells (Promega, USA), with
protein induction as previously described (Kanyenda et al., 2014).
Brieﬂy, cells were homogenised and rCypA protein was puriﬁed by
Immobilized Metal Afﬁnity Chromatography (IMAC) using Ni-NTA
Superﬂow Cartridges (Qiagen, Germany) and dialysed in dialysis buffer
using Slide-A-Lyser cassettes (Thermo Scientiﬁc, USA). Endotoxin was
removed by ﬁltration using a Mustang-E Membrane (Pall Corporation,
USA) and protein purity veriﬁed by coomassie staining of SDS-PAGE gels.
Cyclophilin isomerase activity was conﬁrmed by the Kofron method
(Kofron et al., 1991). Endotoxin testing by the limulus amebocyte lysate
(LAL-Pyrotell T) method conﬁrmed levels were routinely below 0.5
EU/ml.

2.6. Scratch wound healing assays
BV2 microglial cells were seeded in 24 well plates, grown to 90%
conﬂuency, and washed twice with serum-free DMEM prior to experimentation. The cell monolayer was lesioned 3 times in the same location
using a sterile P20 pipette tip to induce an artiﬁcial wound. The
remaining cells were washed with serum-free DMEM before adding 1 mL
of DMEM (2% FBS) containing rCypA protein (10, 100, or 1000 nM) or
vehicle (PBS) to each well. Cultured cells were incubated at 37  C (5%
CO2) for 0, 6 and 24 h post injury. Wound closures were analysed using
the Scratch Edge Detection Macro feature of Image-J (NIH) software and
expressed as percentage area reduction.

2.2. Primary human microglia, cell culture, stimulations and signalling
Primary microglia were puriﬁed from 14 to 19-week-old aborted
human foetuses collected after therapeutic termination and puriﬁed as
previously described (Guillemin et al., 2005). Consent was obtained prior
to collection of tissue, with experimentation approved by the Macquarie
University Human Research and Ethics Committee (Approval number:
REF 5201300330).
BV2 microglia cells were cultured in DMEM (Life Technologies,
Australia) supplemented with 5% foetal bovine serum (FBS), penicillin

2.7. Statistics
Data are presented as mean  SEM of triplicate wells (experiments
were repeated independently three times). Statistical analysis was
2
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3. Results

supernatant, thereby conﬁrming that CypA was actively secreted and not
the result of cell lysis (Fig. 2). In addition, exposure of BV2 microglia cell
cultures to LPS markedly increased ERK1/2 phosphorylation at 15 min,
30 min and 2 h post-exposure, while LY83583 exposure particularly
increased ERK1/2 phosphorylation at 15- and 30-minutes post-exposure.

3.1. CypA and CD147 proteins are expressed by cultured primary human
and BV2 microglial cells

3.3. Recombinant CypA increases the viability but not the rate of cell
proliferation of BV2 microglial cells under basal conditions

Western blot analysis of three human microglial cell lines and BV2
cell lysates revealed a ~18kDa protein consistent with the predicted
molecular weight of CypA (Figure 1A, B). In addition, the three human
microglial cell lines and BV2 cell lysates revealed a ~30kDa and a
~50kDa protein for CD147. The CD147 protein is 27kDa in molecular
weight and the higher molecular weight protein is likely to represent a
glycosylated form of CD147 (Figure 1A, B).

rCypA at 100 and 1000 nM, but not 10 nM signiﬁcantly reduced BV2
microglia cell death (trypan blue positive cells) at 72 h post-treatment (p
< 0.05) when compared to the vehicle treated control (Fig. 3). However,
total and viable BV2 cell numbers was not signiﬁcantly different
following exposure to rCypA at the 10, 100 and 1 μM concentrations,
suggesting the rate of proliferation was not altered.

performed by ANOVA, followed by Tukey multiple comparison or Dunnet post-hoc tests. A value of p < 0.05 was considered to be statistically
signiﬁcant.

3.4. Recombinant CypA increases BV2 microglial cell migration in a
scratch wound healing assay

3.2. CypA secretion and ERK1/2 activation in normal BV2 microglia
cultures and in cultures subjected to inﬂammatory (LPS) and oxidative
stress (LY83583)

Due to the chemotactic effects of CypA, a scratch wound healing assay
was used to determine if CypA could induce the chemotaxis of microglia.
In the wound-healing assay, treatment of BV2 microglia with rCypA
appeared to increase the rate of wound-gap closure at 6- and 24-hours
post-treatment, however only treatment at the 1 μM concentration
reached statistical signiﬁcance compared to the untreated control (p <
0.05; Fig. 4).

Western analysis of BV2 culture supernatants revealed that the cells
constitutively secrete CypA, and that LPS treatment increases CypA
secretion 2 and 4 h after exposure (Fig. 2). Likewise, LY83583 treatment
increases CypA secretion 4 h after exposure (Fig. 2). Importantly, we did
not detect the intracellular cytoskeletal protein β-tubulin in the culture

3.5. Recombinant CypA did not activate the AKT, ERK 1/2 or NF-κB
pathway in BV2 microglial cells
Following the exposure of cell cultures to rCypA (100 nM), Western
blot analysis of BV2 microglia cells lysates revealed no increases in the
level of phosphorylated ERK1/2 or AKT compared to vehicle control.
Similarly, rCypA treatment did not appear to cause IκB degradation in
BV2 cells (Fig. 5).
3.6. IL-6 induced ERK1/2 signalling in BV2 microglia cells, but rCypA did
not induce the secretion of IL-6
IL-6 is associated with tumour cell invasion, angiogenesis, tumour cell
proliferation and poorer prognosis in GBM (Chang et al., 2005; Kudo
et al., 2009). Therefore, we tested if IL-6 can activate the ERK 1/2
pathway in BV2 microglia cells. Western blot analysis of BV2 microglia
cell lysates following exposure of cell cultures to IL-6 for 24 h at 4 nM, but
not 0.04 or 0.4 nM, revealed an increase in the levels of phosphorylated
ERK1/2 as compared to the vehicle control (Fig. 6A). Treatment of BV2
microglial cell cultures with rCypA (100 nM) and analysis of culture
supernatant 24 h post-treatment by ELISA did not detect an increase in
IL-6 levels when compared to the vehicle control (Fig. 6B).
4. Discussion
GBM tissues often contain non-malignant cells, in particular, tumourassociated microglia. Microglia are an essential component of the tumour
microenvironment and are estimated to make up approximately 30% of
GBM (Kostianovsky et al., 2008). Studies have reported that CypA, a
potent chemokine linked to cancer proliferation and metastasis, is
overexpressed in GBM tissue (Matthews et al., 2018; Sun et al., 2011).
Given the known effects of CypA in the promotion of chemotaxis, the
present study sought to investigate the role of microglia as a potential
source and target of extracellular CypA. In doing so, we demonstrate for
the ﬁrst time that human primary microglial cells and BV2 microglial
cells express CypA, and that BV2 microglia secrete CypA under basal
conditions, and in response to inﬂammatory and oxidative stimuli. In
conditions of hypoxia, as occurs in the tumour microenvironment, CypA
expression has been shown to promote glioma-initiating cell proliferation

Fig. 1. Western blot analysis of primary microglia and BV2 microglia cell lysates (A) Intracellular CypA (~18kDa) and glycosylated CD147 (28–50kDa)
expression was detected in human primary microglial and (B) BV2 cell lysates,
with loading controlled for using β-tubulin protein expression. N ¼ 3. Original
uncropped images of blots are shown in Fig. 1 are presented in Supplementary Fig. 1.
3
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Fig. 2. Western blot and densitometric analysis of
BV2 cell lysates and conditioned media following
treatment with (A) LPS or (B) LY83583 for 0–4 h. Blots
and densitometry show an increase in pERK1/2 signal
at 15min following LPS treatment, when controlled
against total ERK1/2. Secreted CypA was detected in
conditioned media peaking at 2h and 4h, following
LPS treatment. When treated with LY83583, BV2 cell
lysates showed a pERK1/2 signal peaking at 30min,
when controlled against total ERK1/2 levels.
Following LY83583 treatment, an increase in CypA
secretion was detected at 4h. The absence of the
cytoplasmic protein β-tubulin conﬁrmed conditioned
media was free of cell lysate and that the CypA was
actively secreted. Con ¼ untreated control. Values are
presented as mean þ/-SE; N ¼ 3. Original uncropped
images of blots are shown in Fig. 2 are presented in
Supplementary Fig. 2.

Fig. 3. Recombinant CypA protein decreases basal cell death but does not affect cell proliferation in BV2 microglial cells. Total cell counts of BV2 cell cultures after
treatment with vehicle or rCypA protein (A) and viable cell counts (by trypan blue discrimination) of BV2 cell cultures after treatment with vehicle or rCypA protein
(B). Total cell numbers (viable and dead cells) increased across all treatments, and rCypA protein addition did not signiﬁcantly increase cell proliferation. There was no
signiﬁcant increase in viable cells at 48 and 72h post rCypA protein addition compared to vehicle treated cultures (C) Trypan blue positive dead cell counts at 48h and
72h post treatment. Addition of rCypA protein (10 nM and 100 nM) decreased basal cell death at 72h post treatment. Values are presented as mean þ/-SE; N ¼ 3, *p
< 0.05.
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Fig. 4. Recombinant CypA protein enhances BV2 cell migration in a wound-healing assay. A sub-conﬂuent layer of BV2 cells was inﬂicted with a wound and the
resulting gap was imaged at the time of the wound and after 6h and 24h post treatment (A) Images are representative of a typical experiment repeated 3 independent
times. The percentage of wound-gap was analysed by the Image J software, graphed and statistically analysed (B). At 24h, cultures treated with rCypA at the 1 μM
showed enhanced gap closure compared to the vehicle treated cultures. post treatment (p < 0.05). Values are presented as mean þ/-SE; N ¼ 3, *p < 0.05.

Fig. 5. Representative Western blots of rCypA treated BV2
cell lysates with showing no activation of the ERK 1/2,
AKT and NFκB signalling pathways (A) Recombinant CypA
protein (100 nM) did not activate ERK 1/2 or AKT phosphorylation in the BV2 cells when compared to the time
point controls. No IκB degradation was observed following
rCypA treatment (100 nM), indicating no activation of the
NFκB signalling pathway. The PBS vehicle was used for
time point controls in these cell-signalling experiments. C
¼ vehicle control. N ¼ 3. Original uncropped images of
blots are shown in Fig. 5 are presented in Supplementary
Fig. 3.
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microglial cells. However, further work is needed to conﬁrm that CypA
mediates these actions via the CD147 receptor.
CypA is known to promote tumour growth and correlates with poor
clinical outcomes in various cancers (Nakano et al., 2017), however the
exact mechanism of this activity remains unclear. In an effort to identify
the mechanisms responsible for the CypA-induced cell survival and
migration of BV2 cells, key signal pathways were studied following recombinant CypA treatment. The results from this study showed rCypA
treatment did not induce signiﬁcant changes in the expression of phosphorylated AKT, ERK1/2 or NFκB pathways. These results were somewhat surprising as we have previously shown that CD147-mediated
activation with rCypA mediates ERK1/2-dependent survival pathways in
neurons during in vitro oxidative and ischemic injury (Boulos et al.,
2007). In the present study, while we demonstrated activation of ERK1/2
and AKT pathways following LPS and oxidative stress, subsequent experiments showed rCypA induced cell migration occurred independent of
any induced stress. However, it is possible that incubation in serum-free
media for a 72-hour time point may have provided conditions of stress to
allow for CypA-mediated survival pathway activation, which was not
present in western blot experiments. However, the lack of such downstream effects observed following rCypA treatment in the present study is
surprising, and may therefore be a product of the BV2 cell line.
To further investigate the signalling properties of BV2 microglia, IL-6
was studied as a cytokine known to be secreted from microglia (W.-Y.
Wang, Tan, Yu and Tan, 2015), and which can activate pro-survival
signalling in cancer cells. We demonstrated that IL-6 could induce
ERK1/2 activation in BV2 microglia cells and conﬁrms that while we did
not detect ERK1/2 activation in BV2 cells exposed to rCypA, such a
pathway is able to be activated following cytokine treatment. Neurons,
astrocytes, microglia and endothelial cells are all essential sources of IL-6
in the CNS, and upon stimulation (such as injury) are capable of actively
secreting IL-6 (Erta et al., 2012). In addition, activated microglia are the
primary source of inﬂammatory cytokines in non-malignant neuronal
diseases (e.g. Alzheimer's disease) (Bachstetter and Van Eldik, 2010).
Therefore, the inability of rCYPA to induce IL-6 secretion in microglia
was surprising, however, while the morphological appearance of
microglia located in or around GBM tumours suggests microglia activation, such cells do not release the prototypical inﬂammatory cytokines
such as TNF-α or IL-6 (Gabrusiewicz et al., 2011; Sliwa et al., 2007).
Nevertheless, the results in the present study may also be a result of the
BV2 cell line, and requires further conﬁrmation in primary microglia.
Microglia and astrocytes play a protective and curative function in the
CNS against pathogens by producing cytokines and chemokines that
promote the recruitment of circulating immune cells. Peripheral bacterial
infections are recognised by toll like receptors (TLR) which activate
innate immune cells. The activation of TLRs can lead to the upregulation
of NFKB which can increase the transcription of genes encoding the IL-1
family cytokines and TNF with downstream effects of cytokine secretion
that act on the innate immune system and ﬁght infections. In our study,
we showed that LPS induces the secretion of CypA and LPS is known to
trigger TLRs to induce its effects.
The ﬁnding that microglia can secrete CypA in response to oxidative
stress and pro-inﬂammatory stimulation has broader implications in
neuroinﬂammation. Stress and inﬂammation are pathogenic processes,
known to induce the onset and progression of many diseases. Chronic
stress due to physical and environment stimuli, such as those present in
the GBM microenvironment, can induce several unwanted changes
within the CNS, which includes secretion of high levels of proinﬂammatory cytokines and chemokines, increased oxidative stress and
neuroinﬂammation (Kempuraj et al., 2019). Stress induced neuroinﬂammation can involve mast cell activation, the subsequent generation
of proinﬂammatory cytokines (Caraffa et al., 2018), which in turn can
activate glial cells. A recent report indicates targeting inﬂammation
through the administration of natural ﬂavonoid compounds could inhibit
neuroinﬂammation and the severity of neurodegenerative diseases
(Theoharides and Kavalioti, 2018; Theoharides and Tsilioni, 2018).

Fig. 6. Treatment of BV2 cells with IL-6 (24 h) and recombinant CypA (A) IL-6
induces pERK1/2 expression at a 4 nM dose, but not at lower treatment doses
(B) Treatment of BV2 cells with rCypA (100 nM) does not enhance the secretion
of IL-6 in culture medium. C ¼ vehicle control. Values are presented as mean
þ/-SE; N ¼ 3. Original uncropped images of blots are shown in Fig. 6 are presented in Supplementary Fig. 4.

and radiotherapy resistance (G. Wang et al., 2017). The expression of the
main CypA receptor, CD147, positively correlates with GBM severity and
patient outcome (Matthews et al., 2018). The present study supports the
hypothesis that microglia can contribute to the tumour microenvironment via the actions of CypA. Similar to previous studies on primary
microglia and RA2 microglial cells (Inoue et al., 1999), we detected
strong CD147 expression in human primary microglial and BV2 microglial cells. The CD147 protein appeared glycosylated, which is a necessary requirement for CypA induced CD147 signalling.
Given that the GBM microenvironment harbours areas of hypoxia and
oxidative stress, we also investigated CypA secretion and signalling
following inﬂammatory and oxidative stress stimulation. We observed
increased levels of CypA secretion in BV2 microglia cell culture supernatants and increased ERK1/2 activation in BV2 cells following inﬂammatory and oxidative stress stimulation. The secretion of CypA in
response to the pro-inﬂammatory molecule LPS is in line with the ability
of macrophages to secrete CypA in response to inﬂammatory stressors
(Sherry et al., 1992). These ﬁnding are consistent with previous studies in
showing that CypA is secreted by vascular smooth muscle cells in
response to oxidative stress (Jin et al., 2000).
Our observation that BV2 microglia can secrete CypA provides evidence that extracellular CypA may play a role within the GBM microenvironment. While, extracellular rCypA did not induce the proliferation of BV2 cells, it did enhance BV2 cell survival. The cell survival
promoting effects of CypA may be mediated by CD147-mediated ERK1/2
anti-apoptotic signalling (Choi et al., 2007). Further, as CypA can act as a
potent chemokine for immune cells, we demonstrated that rCypA enhances BV2 microglia migration in a scratch wound-gap healing.
In the context of GBM, targeting of CypA with cyclosporine A resulted
in the inhibition of microglial mediated GBM invasion (Sliwa et al.,
2007). In addition, CypA-induced cell-migration and invasion has been
shown to be mediated by the CD147 receptor (Guo et al., 2015; C.-h.
Wang et al., 2014), which as we demonstrate is expressed by BV2
6
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These reports also suggest that the interaction of mast cells and microglia
in the hypothalamus could induce stress mediated neuroinﬂammation.
In summary, we have demonstrated that the BV2 microglial cell line
secretes CypA, and that rCypA can promote cell viability and chemotaxis
in these cells. In addition, we have shown that inﬂammatory and
oxidative stress stimulates the secretion of CypA by BV2 microglial cells.
Deﬁnitive elucidation of the cell-signalling pathways by which CypA
mediates its cell-supporting role in microglia will probably require the
use of organotypic brain slice cultures, in which quiescent primary
microglial cells are more likely to be found. Finally, our ﬁndings are
important because they indicate that extracellular CypA is likely to be
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